Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 4/20 | 0.61 |
| ▸ | PTPRC | P08575 | 2/20 | 0.59 |
| ▸ | CSNK2A2 | P19784 | 7/20 | 0.51 |
| ▸ | CSNK2B | P67870 | 7/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 7/20 | 0.51 |
| ▸ | CSNK2A3 | Q8NEV1 | 7/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CDC25A | P30304 | 1/20 | 0.50 |
| ▸ | CDC25B | P30305 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598301 | 0.81 | TTR (0.88) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL71021 | 0.81 | TTR (0.88) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL31436145 | 0.81 | TTR (0.88) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL599578 | 0.77 | TTR (0.81) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL31686219 | 0.77 | PTPRC (0.84) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL31086890 | 0.77 | TTR (0.80) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL600296 | 0.77 | TTR (0.80) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6901581 | 0.77 | TTR (0.80) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9173829 | 0.77 | TTR (0.72) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL30610011 | 0.76 | TTR (1.00) | TTRPTPRCKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140227689-A1 | NOVEL METHODS FOR QUANTIFICATION OF MICRORNAS AND SMALL INTERFERING RNAS | EXIQON A/S (DK) | 2014-08-14 | — | — | US | disclosed |
| US-8383344-B2 | Methods for quantification of microRNAs and small interfering RNAs | EXIQON A/S (DK) | 2013-02-26 | — | — | US | disclosed |
| US-8192937-B2 | Methods for quantification of microRNAs and small interfering RNAs | EXIQON A/S (DK) | 2012-06-05 | — | — | US | disclosed |
| EP-1735459-B1 | METHODS FOR QUANTIFICATION OF MICRORNAS AND SMALL INTERFERING RNAS | EXIQON AS (DK) | 2012-01-25 | — | — | EP | disclosed |
| US-20110076675-A1 | NOVEL METHODS FOR QUANTIFICATION OF MICRORNAS AND SMALL INTERFERING RNAS | EXIQON A/S (DK) | 2011-03-31 | — | — | US | disclosed |
| US-7504495-B2 | Quencher compositions comprising anthraquinone moieties | EXIQON A/S (DK) | 2009-03-17 | — | — | US | disclosed |
| US-7504495-B2 | Quencher compositions comprising anthraquinone moieties | EXIQON A/S (DK) | 2009-03-17 | — | — | US | disclosed |
| WO-2008040355-A2 | NOVEL METHODS FOR QUANTIFICATION OF MICRORNAS AND SMALL INTERFERING RNAS | EXIQON A/S (DK) | 2008-04-10 | — | — | WO | disclosed |
| US-20080076674-A1 | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer | EXIQON A/S (DK) | 2008-03-27 | — | — | US | disclosed |
| US-20050272075-A1 | Novel methods for quantification of microRNAs and small interfering RNAs | QIAGEN GMBH (DE) | 2005-12-08 | — | — | US | disclosed |
| US-20050227254-A1 | Quencher compositions comprising anthraquinone moieties | QIAGEN GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
| EP-1538154-A1 | Quencher composition comprising anthraquinone moieties | Exiqon A/S (DK) | 2005-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227254-A1 | Quencher compositions comprising anthraquinone moieties | ANXA5, SUN2, ANXA3 | TTR 3373/4885PTPRC 3481/4885CSNK2A2 2847/4885 |
| US-20080076674-A1 | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer | SNRPE, SNRPA, NOP56 | TTR 3844/4885PTPRC 2414/4885CSNK2A2 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.